Receptos intends to raise $86.3 million in an initial public offering to fund mid-stage clinical trials for its once-daily, oral multiple sclerosis drug RPC1063 and the antibody RPC4046 for the treatment of eosinophilic esophagitis (EoE).
The San Diego-based company licensed RPC4046 in March from AbbVie, but the Abbott spinout retained the right to enter into a global collaboration for the humanized anti-interleukin-13 (IL-13) antibody based...